Recruiting studies: Nsclc Stage Ii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924 Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subje
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07175220 TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2 · 1 location(s) · TYK Medicines, Inc · NCT05948813 Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06939127 Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
Phase 2 · 3 location(s) · Hackensack Meridian Health · NCT05715229 A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small C
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT07082179 Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immun
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06694454 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Phase 1/Phase 2 · 5 location(s) · Anbogen Therapeutics, Inc. · NCT05532696 Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Nanchang University · NCT06554613 IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT07408635 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751 Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: RO
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT01639508 A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464 Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Chinese University of Hong Kong · NCT07379476 AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT05377658 Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
Phase N/A · 3 location(s) · Vanderbilt-Ingram Cancer Center · NCT00897117 Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/Phase 2 · 1 location(s) · China Medical University Hospital · NCT06071013 Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06014827 Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer
Phase 2 · 1 location(s) · The Canadian College of Naturopathic Medicine · NCT05849129 Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After R
Phase N/A · 1 location(s) · Liaoning Cancer Hospital & Institute · NCT06109454 A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Phase 1/Phase 2 · 103 location(s) · AstraZeneca · NCT06996782 Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07528274 A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 2 · 2 location(s) · Shanghai Henlius Biotech · NCT06907615 Pembrolizumab for Advanced NSCLC and PS 2-3
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT05589818 Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149 TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemo
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330037 A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06769295 Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/Phase 2 · 12 location(s) · Vivace Therapeutics, Inc · NCT04665206 Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
Phase 2 · 1 location(s) · Tang-Du Hospital · NCT07596121 A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC
Phase 2 · 4 location(s) · Guangdong Association of Clinical Trials · NCT07375316

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.